Compositions and methods for the identification, assessment, prevention and therapy of cardiovascular disease
AssigneeMillennium Pharmaceuticals, Inc.
InventorJeanette McCarthy
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating cardiovascular diseases.
Claims51
A method of diagnosing or aiding in the diagnosis of a cardiovascular disease in a patient, the method comprising comparing:
- a) the level of a thrombospondin marker in a sample, and
- b) the normal level of thrombospondin marker in a control non-cardiovascular disease sample,
- wherein a significant difference between the level of thrombospondin marker in the patient sample and the normal thrombospondin marker level is an indication that the patient is afflicted with or predisposed to cardiovascular disease.
A method for predicting the likelihood that an individual will have a cardiovascular disease, the method comprising comparing:
- a) the level of a thrombospondin marker in a sample, and
- b) the normal level of a thrombospondin marker in a control non-cardiovascular disease sample,
- wherein a significantly different level of the thrombospondin marker in the sample, relative to the normal level, is an indication that the patient has an increased likelihood of having a cardiovascular disease.
A method for monitoring the progression of cardiovascular disease in a patient, the method comprising:
- a) detecting in a patient sample at a first point in time, the level of a thrombospondin marker;
- b) repeating step a) at a subsequent point in time;
- and
- c) comparing the level of thrombospondin marker detected in steps a) and b), and therefrom monitoring the progression of cardiovascular disease in the patient.
A method of assessing the efficacy of a compound for inhibiting cardiovascular disease in a patient, the method comprising comparing:
- a) the level of a thrombospondin marker in a first sample obtained from the patient and maintained in the presence of the compound, and
- b) the level of a thrombospondin marker in a second sample obtained from the patient and maintained in the absence of the compound,
- wherein a significantly enhanced level of a thrombospondin marker in the first sample, relative to the second sample, is an indication that the compound is efficacious for inhibiting cardiovascular disease in the patient.
A method of assessing the efficacy of a therapy for inhibiting cardiovascular disease in a patient, the method comprising comparing:
- a) the level of a thrombospondin marker in the first sample obtained from the patient prior to providing at least a portion of the therapy to the patient, and
- b) the level of a thrombospondin marker in a second sample obtained from the patient following provision of the portion of the therapy,
- wherein a significantly enhanced the level of a thrombospondin marker in the second sample, relative to the first sample, is an indication that the therapy is efficacious for inhibiting cardiovascular disease in the patient.
A kit for assessing whether a patient is afflicted with or predisposed to cardiovascular disease, the kit comprising reagents for assessing the level of a thrombospondin marker.
A kit for assessing the suitability of a compound for inhibiting cardiovascular disease in a patient, the kit comprising:
- a) the compound;
- and
- b) a reagent for assessing expression of a thrombospondin marker.
Dependencies are inferred from the claim text.